VaxInnate Updates Plans to Advance Lead Vaccine Candidate, VAX2012Q in Elderly
October 08, 2014 09:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Oct. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, provided an update on
clinical development plans for...
Dynavax Appoints David Novack as Senior Vice President, Operations and Quality
March 21, 2013 16:00 ET
|
Dynavax Technologies
BERKELEY, CA--(Marketwire - Mar 21, 2013) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the appointment of David Novack to the position of Senior Vice President, Operations and...
DGAP-News: Hemispherx Biopharma Announces 9th Clinical Investigators Conference: Ampligen Clinical Trials Highlighted
March 08, 2011 03:03 ET
|
EQS Group AG
Hemispherx Biopharma, Inc.
08.03.2011 09:00
---------------------------------------------------------------------------
Conference Explores Potential Relationships Between Chronic Fatigue...
Hemispherx Biopharma Announces 9th Clinical Investigators Conference: Ampligen Clinical Trials Highlighted
March 07, 2011 14:25 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 7, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) ("Hemispherx" or the "Company") announced that the Company conducted its 9th Clinical Investigators Conference...
Crucell Announces 2004 Annual Results
January 24, 2005 09:01 ET
|
Crucell N.V.
LEIDEN, Netherlands, Jan. 24, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Nasdaq:CRXL) (Euronext:CRXL) today announced its 2004 financial results. Revenue for the year ended...
Crucell Reports Third Quarter 2004 Results
October 12, 2004 08:43 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Oct. 12, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) today announced its financial results for the third quarter of 2004. Crucell...
Crucell Announces PER.C6(R) Licensing Agreement with Vaxin for Adenoviral Vaccines
September 13, 2004 08:14 ET
|
Crucell N.V.
LEIDEN, The Netherlands, Sept. 13, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq:CRXL) announced today that it has signed a non-exclusive PER.C6(R) technology license...